DEF: Aimfinity Seeks Extension, NTA Waiver for Docter Merger

Aimfinity Investment Corp. I seeks shareholder approval to extend its business combination deadline to July 28, 2026, and waive the net tangible asset requirement to facilitate the Docter Inc. merger.

Summary

• Aimfinity Investment Corp. I (AIMA) is holding an Extraordinary General Meeting on October 27, 2025, to vote on three key proposals.
• The Charter Amendment Proposal seeks to extend the deadline for completing a business combination from October 28, 2025, up to nine additional one-month extensions, totaling nine months, to July 28, 2026. Each monthly extension requires the Sponsor to deposit $500 into the Trust Account.
• The NTA Requirement Amendment Proposal aims to eliminate the existing charter limitation that prevents AIMA from redeeming public shares if it would cause net tangible assets to fall below US$5,000,001, providing greater flexibility for the Docter Business Combination.
• An Adjournment Proposal will also be presented, allowing the Board to adjourn the meeting if insufficient votes are received for the other proposals or if more time is needed.
• These proposals are crucial for the consummation of the Docter Business Combination, which shareholders previously approved on March 27, 2025.
• In connection with the Business Combination EGM, 1,072,957 New Units were tendered for redemption and are currently held in a segregated account.
• The estimated per-share redemption price from the Trust Account is approximately $12.80 as of the Record Date (September 29, 2025).
• Public shareholders have the option to redeem their New Units for cash if the Charter Amendment and/or NTA Requirement Amendment Proposals are approved, but will forfeit their Class 2 Warrants.
• The Board unanimously recommends voting FOR all three proposals.

Sentiment

Score: 3

Explanation: While the company is actively pursuing a business combination with Docter Inc. and the target has promising technology, the repeated extensions, significant shareholder redemptions, delisting from Nasdaq, and the need to waive critical net tangible asset requirements indicate substantial operational and financial challenges. The low extension fee and the unfavorable warrant forfeiture terms for redeeming shareholders further highlight the precarious situation. The overall sentiment is negative due to these compounding issues, despite the continued efforts to complete the merger.

Positives

• The proposed extension of the business combination deadline provides more time to complete the Docter Business Combination, potentially avoiding liquidation.
• Elimination of the Net Tangible Asset (NTA) requirement offers greater flexibility to consummate the Docter Business Combination, regardless of the level of redemptions.
• The Sponsor's commitment to deposit $500 for each monthly extension demonstrates continued support for the business combination.
• Shareholders previously approved the Docter Business Combination on March 27, 2025, indicating a general consensus for the merger.
• Docter Inc. is developing non-invasive blood sugar trend monitoring technology and biological radar wave technology, with a recent Memorandum of Understanding (MOU) with Harvard Medical School for 10,000 watches for a Long Covid research project, highlighting potential for growth in advanced medical research.

Negatives

• The necessity for further extensions suggests ongoing difficulties or delays in closing the Docter Business Combination.
• Shareholders who elect to redeem their public shares will forfeit their Class 2 Warrants, which could represent a loss of potential future value.
• The company's units, new units, and Class 1 warrants are currently traded over-the-counter (OTCID) and may have extremely limited liquidity, making it difficult for shareholders to sell at favorable prices.
• If the NTA Requirement Amendment is approved, failure to meet Nasdaq's initial listing requirements could result in the combined entity's shares not listing on Nasdaq, leading to reduced liquidity and potential compliance with penny stock trading rules.
• Additional expenses, including extension fees, will be incurred if the Charter Amendment is approved, increasing the cost of completing the business combination.
• The company's securities were removed from the Nasdaq Global Market to OTCID on May 5, 2025, indicating a downgrade in listing status.
• The location of the CEO, Chairman, and one independent director in Taiwan may complicate the enforcement of U.S. legal rights or judgments for U.S. investors.
• There is a risk that the company could be deemed an unregistered investment company under the Investment Company Act of 1940, which could force liquidation and cause warrants to expire worthless.

Risks

• Inability to obtain shareholder approval for the Charter Amendment Proposal and NTA Requirement Amendment Proposal.
• Failure to complete the initial business combination (Docter Business Combination) by the extended deadline of July 28, 2026.
• Significant redemptions by public shareholders, potentially leaving insufficient cash to consummate the business combination or causing net tangible assets to fall below $5,000,001 if the NTA Requirement Amendment is not approved.
• Volatility and extremely limited liquidity of the company's public securities (Units, New Units, Class 1 Warrants) on the OTCID market, which may prevent shareholders from disposing of their securities at favorable prices.
• The Trust Account being subject to claims of third parties, which could reduce the per-share redemption price for public shareholders.
• If the NTA Requirement Amendment is approved, the combined entity's failure to meet Nasdaq's initial listing requirements could result in its ordinary shares not listing on Nasdaq, leading to reduced market liquidity, potential application of penny stock rules, and a decreased ability to raise additional funds in the future.
• Risk of being deemed an unregistered investment company under the Investment Company Act of 1940, which could severely restrict activities, force liquidation, and cause warrants to expire worthless.
• Difficulties for U.S. investors to enforce civil liability against officers and directors located in Taiwan due to the absence of treaties for reciprocal recognition and enforcement of foreign judgments.
• Potential impact of U.S. Foreign Investment Regulations (CFIUS) if an alternative business combination with a U.S. business is pursued, which could block or delay the transaction.
• Conflicts of interest for Insiders (Sponsor, directors, and officers) due to their financial interests in completing a business combination, which may influence their decisions.

Future Outlook

The company aims to complete the Docter Business Combination by October 28, 2025, with potential extensions up to July 28, 2026, to allow PubCo to become a publicly traded company. Efforts are underway to qualify for Nasdaq listing post-merger. Docter Inc.'s focus on non-invasive health monitoring and biological radar wave technology, including a recent MOU with Harvard Medical School, suggests future growth potential in health tech. The company may seek further extensions beyond July 28, 2026, if necessary, subject to shareholder approval.

Management Comments

• The Board has determined that it is in the best interests of the Company's shareholders to approve the Charter Amendment Proposal to extend the Combination Period.
• The Board has determined that it is in the best interests of the Company's shareholders to approve the NTA Requirement Amendment Proposal to give the parties to the Business Combination Agreement additional flexibilities to consummate the Docter Business Combination.
• The Board unanimously recommends that shareholders vote FOR each of the Charter Amendment Proposal, the NTA Requirement Amendment Proposal, and, if presented, the Adjournment Proposal.
• The Company has committed to not to seek to withdraw any fund for tax payment or dissolution expenses from the Trust Account in connection with the extraordinary general meeting previously held on January 9, 2025.
• The Company is currently working diligently with Docter and the other parties to the Business Combination Agreement to qualify for Nasdaq listing.

Industry Context

This filing highlights the persistent challenges faced by Special Purpose Acquisition Companies (SPACs) in meeting initial business combination deadlines, necessitating repeated extensions. The proposed elimination of the Net Tangible Asset (NTA) requirement reflects the evolving regulatory environment for SPACs, particularly in light of the SEC's SPAC Final Rules effective July 1, 2024, and the strategic adaptations companies are making to avoid 'penny stock' designations. The company's recent delisting from Nasdaq Global Market to OTCID on May 5, 2025, underscores a broader trend of SPACs struggling to maintain major exchange listings due to high redemptions and valuation pressures. Docter Inc.'s focus on non-invasive health monitoring and biological radar wave technology aligns with significant growth trends in the health tech sector, with the Harvard Medical School MOU indicating potential for substantial market penetration in medical research.

Comparison to Industry Standards

• The extension fees of $500 per month are significantly lower than previous extension payments made by the Sponsor ($85,000, $60,000, and $0.05 per public share), which is a notable deviation from typical SPAC extension costs and may suggest a highly diluted trust or limited sponsor capital commitment for extensions.
• The forfeiture of Class 2 Warrants upon redemption is explicitly stated as 'different from other special purpose acquisition companies, which generally provide that holders of shares that are redeemed can keep the warrants associated with those shares,' making this a less favorable term for redeeming shareholders compared to industry norms.
• The company's reliance on the Exchange Rule (listing on OTCID) to avoid penny stock designation, rather than the NTA Rule, is an adaptation to regulatory changes and potentially reduced asset base, a strategy that may become more common for SPACs facing NTA challenges.
• The current trading of units on OTCID with 'extremely limited liquidity' is below the standard expected for a company aiming for a Nasdaq listing post-merger, indicating significant market challenges compared to peers on major exchanges.

Corporate Governance

Related Party Transactions

• The Sponsor (Aimfinity Investment LLC) or its affiliates/designees are obligated to deposit $500 into the Trust Account for each one-month extension of the business combination period.
• I-Fa Chang (Chairman, CEO, director, and manager/sole member of the Sponsor) and other Insiders (including Xuedong (Tony) Tian and Chun-Cheng Su) collectively own approximately 66.4% of the company's Ordinary Shares and have agreed not to redeem their shares.
• Insiders have waived their rights to liquidating distributions from the Trust Account with respect to any Ordinary Shares held by them.
• The Sponsor, officers, and directors or their affiliates may provide Working Capital Loans to the company, which can be converted into private units at $10.00 per unit, up to $1,500,000.
• The Sponsor has agreed to indemnify AIMA to ensure that the proceeds in the Trust Account are not reduced below $10.20 per public share by claims of prospective target businesses or third parties, provided such parties have executed waivers of access to the Trust Account.
• Unsecured promissory notes (First EGM Note, Second EGM Note, Third EGM Note) were issued to I-Fa Chang for previous extension payments, which are convertible into private placement units.

Stakeholder Impact

• **Shareholders**: Public shareholders face a critical decision regarding whether to redeem their shares (and forfeit warrants) or hold them for the extended business combination. Those who hold face continued uncertainty, potential dilution, and limited liquidity on the OTCID market. Insiders benefit from the extension as it preserves their investment in Founder Shares and potential conversion of loans.
• **Docter Inc.**: The extension provides Docter with additional time to complete the merger and potentially achieve a Nasdaq listing, which is crucial for its future public market access.
• **Creditors**: The company's obligations under Cayman Islands law to provide for claims of creditors are explicitly mentioned in the event of liquidation. The Sponsor's indemnity agreement offers some protection for the Trust Account against certain third-party claims.
• **Employees**: While not directly mentioned, the successful completion of the business combination would provide stability and a clear path forward for the employees of the combined entity.

Next Steps

• Shareholders are to vote on the Charter Amendment Proposal, NTA Requirement Amendment Proposal, and Adjournment Proposal at the Extraordinary Meeting on October 27, 2025.
• If approved, the company will have until October 28, 2025, to consummate the Docter Business Combination, with potential extensions up to July 28, 2026.
• The Sponsor or its affiliates/designees must deposit $500 for each monthly extension into the Trust Account, with the first payment due by October 28, 2025.
• The company will continue working diligently with Docter to qualify for Nasdaq listing post-merger.
• Public shareholders must decide on exercising their redemption rights in connection with the proposals by October 23, 2025.
• If the Docter Business Combination is consummated, PubCo will become a publicly traded company.
• If the business combination is not completed by the final deadline, the company will be obligated to liquidate and redeem all remaining public shares.

Key Dates

Recommendation

The company is navigating a complex and challenging period, marked by repeated delays in completing its business combination, significant shareholder redemptions, and a recent delisting from Nasdaq to OTCID. While the proposed Docter Inc. merger presents a potential future, the need for further extensions and the waiver of the Net Tangible Asset requirement highlight underlying operational and financial vulnerabilities. The unfavorable terms for redeeming shareholders (warrant forfeiture) and the extremely limited liquidity on the OTCID market add to the risk profile. A 'hold' recommendation is appropriate for existing investors who have already absorbed significant uncertainty, acknowledging the continued pursuit of the merger while recognizing the elevated risks and the company's current precarious position. New investors should exercise extreme caution due to the high risk and uncertainty.

Keywords

SPAC, Aimfinity Investment Corp. I, AIMA, Docter Inc., Business Combination, Merger, Proxy Statement, Shareholder Meeting, Charter Amendment, NTA Requirement, Net Tangible Assets, Redemption Rights, Trust Account, Extension, Nasdaq Listing, OTC Market, Investment Company Act, Corporate Governance, SEC Filing, Financial Reporting, Risk Management